FDA Approval Pitfalls, Surrogate Endpoints, and Postapproval Evidence Gaps: Scoping Review with ☸️SAIMSARA
SAIMSARA Journal · 22.05.2026 · 1 (3)
DOI: 10.62487/saimsarae25de34b ↗Kurz gefasst
Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 22.05.2026. Die Arbeit nennt 86 Literaturangaben.
Abstract (Originalsprache)
To identify and synthesize recurring pitfalls in FDA approval processes and postapproval implementation, emphasizing evidentiary uncertainty, surrogate endpoints, expedited pathways, trial design limitations, transparency gaps, population representativeness, safety monitoring, real-world effectiveness, and access after approval. The review uses 86 references and builds its evidence map from 69 original studies with 723986 total participants/sample observations (topic-deduplicated ΣN). Across diverse product classes and indications, the dominant signal is that FDA approval frequently occurs under residual evidentiary uncertainty rather than after definitive demonstration of patient-centered benefit, with recurrent reliance on surrogate endpoints, thin pivotal trial packages, and expedited pathways. This pattern is reinforced by underrepresentation of key demographic groups, incomplete transparency, and delayed or failed confirmatory trials, where only 43% of accelerated cancer approvals demonstrated clinical benefit in confirmatory studies. The findings suggest that clinicians, payers, and patients should interpret approval as a regulatory milestone rather than a guarantee of comparative effectiveness, equitable access, or real-world safety. Given the scoping nature of this synthesis and the heterogeneity of included evidence, future research should prioritize timely confirmatory randomized trials, indication-specific surrogate validation, and structured postapproval surveillance to close the gap between regulatory authorization and demonstrated patient benefit.
Zitieren
APA
(2026). FDA Approval Pitfalls, Surrogate Endpoints, and Postapproval Evidence Gaps: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(3). https://doi.org/10.62487/saimsarae25de34b
Vancouver
FDA Approval Pitfalls, Surrogate Endpoints, and Postapproval Evidence Gaps: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(3). doi:10.62487/saimsarae25de34b
BibTeX
@article{euvimed2026,
title = {FDA Approval Pitfalls, Surrogate Endpoints, and Postapproval Evidence Gaps: Scoping Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
volume = {1},
number = {3},
doi = {10.62487/saimsarae25de34b}
}
EUVIMED